Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/07/15Syros Pharmaceuticals Appoints David A. Roth, M.D., as Chief Medical Officer
CAMBRIDGE, Mass., December 7, 2015 – Syros Pharmaceuticals today announced that David A. Roth, M.D., an industry leader in oncology and hematology drug development, joined the Company as its first Chief Medical Officer. Dr. Roth will provide strategic and operational leadership for all the Company’s clinical development activities and functions.“Syros is rapidly advancing on our goal of becoming a development-stage company, with plans to initiate a Phase 2 study with our lead program and a ... 
Printer Friendly Version
12/05/15Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of First-in-Class Selective CDK7 Inhibitor in Models of Acute Leukemias
CAMBRIDGE, Mass., December 5, 2015 – Syros Pharmaceuticals today announced the results of new preclinical studies in which SY-351, one of its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitors, was observed to have significant anti-tumor activity, including inducing and maintaining complete tumor regression, in in vivo models of acute leukemias. These data are being presented at the American Society of Hematology (ASH) Annual Meeting. “Our CDK7 inhibitor program high... 
Printer Friendly Version
11/10/15Syros Pharmaceuticals Announces Issuance of U.S. Patents Related to Its Gene Control Drug Discovery and Development Platform
CAMBRIDGE, Mass., November 10, 2015 – Syros Pharmaceuticals today announced that the U.S. Patent and Trademark Office issued two patents related to the Company’s proprietary gene control platform for mapping and drugging crucial genes that become dysregulated in disease. The covered inventions include methods for identifying specialized regions of DNA, known as super-enhancers, which are part of the foundation of the Company’s drug discovery and development platform.“Our gene control platfo... 
Printer Friendly Version
11/05/15Syros Pharmaceuticals to Present Preclinical Data on First-­in-­Class Selective CDK7 Inhibitor Program at American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., November 5, 2015 – Syros Pharmaceuticals today announced that it will present preclinical data on its first-in-class selective cyclin-dependent kinase 7 (CDK7) program in acute leukemias at the American Society of Hematology (ASH) Annual Meeting taking place December 5-8 in Orlando, Florida.CDK7 Inhibition as a Novel Treatment Strategy for Acute Leukemias Certain cancers, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), are dependent on hi... 
Printer Friendly Version
10/19/15Syros Pharmaceuticals Appoints Industry Leader Marsha H. Fanucci to its Board of Directors
Scientific Co‑Founder James E. Bradner Steps Down from Board Following Appointment as President of NIBRCAMBRIDGE, Mass., October 19, 2015 – Syros Pharmaceuticals, the industry pioneer in gene control, today announced the appointment of Marsha H. Fanucci to the company’s Board of Directors. Ms. Fanucci brings 25 years of experience in biopharmaceutical financial management and strategic business operations. “With her extensive leadership and financial management experience, Mars... 
Printer Friendly Version
09/30/15FierceBiotech names Syros Pharmaceuticals as one of its “Fierce 15” Biotech Companies of 2015
Cambridge, Mass. – September 30, 2015 – Syros Pharmaceuticals, the industry pioneer in gene control medicines, today announced that it has been named by FierceBiotech as one of 2015’s Fierce 15 biotechnology companies. The award designates Syros as one of the most promising private companies in the biotech industry. Syros, established in 2013, discovers and develops gene control medicines using a proprietary platform to systematically identify gene regulatory alterations that give... 
Printer Friendly Version
09/27/15Pharma gives drug development the Hollywood treatment; The Boston Globe. Weisman, Robert
... 
Printer Friendly Version
09/27/15Syros Pharmaceuticals Hacking the Genetic Operating Systems; FierceBiotech. Garde, Damian.
... 
Printer Friendly Version
09/24/15Syros Pharmaceuticals' Scientific Co-Founder Appointed President of Novartis Institutes for BioMedical Research
CAMBRIDGE, Mass., September 24, 2015 – Syros Pharmaceuticals, the industry pioneer in gene control, today recognized its scientific co-founder and board member James E. (Jay) Bradner, M.D. on his appointment as President of the Novartis Institutes of BioMedical Research (NIBR). Dr. Bradner will begin his tenure as President of NIBR in March.   Together with fellow scientific co-founders Richard Young, Ph.D., and Nathanael Gray, Ph.D., Dr. Bradner has helped to shape Syros’ novel... 
Printer Friendly Version
09/24/15Syros Pharmaceuticals Licenses Clinical-Stage RARα Agonist to Develop and Commercialize for Genomically-Defined Cancer Populations Identified by Gene Control Platform
‐ Phase 2 clinical trial in acute myeloid leukemia (AML) / myelodysplastic syndrome (MDS) patients with gene control biomarker discovered by Syros planned in the first half of 2016 -‐ Provides validation for proprietary gene control target and biomarker discovery and development platform -CAMBRIDGE, Mass., September 24, 2015 – Syros Pharmaceuticals, the industry pioneer in gene control, announced today that it entered into an exclusive license agreement with the Japanese oncology company TMRC Co... 
Printer Friendly Version
09/24/15Syros Pharmaceuticals Announces New Publication Highlighting the Strong Potential of CDK7 Inhibition in Difficult-to-Treat Cancer
CAMBRIDGE, Mass., September 24, 2015 – Syros Pharmaceuticals, the industry pioneer in gene control, announced today the publication of a new study co-authored by Jean Zhao, PhD of the Dana-Farber Cancer Institute, and Syros scientific co-founders Nathanael Gray, PhD, and Richard Young, PhD, that demonstrates the central role played by cyclin-dependent kinase 7 (CDK 7) in the growth of a highly aggressive form of breast cancer, and the strong potential of selective inhibition of CDK7 as a ... 
Printer Friendly Version
09/21/15Syros Pharmaceuticals Appoints Kyle Kuvalanka as Chief Operating Officer
CAMBRIDGE, Mass., September 21, 2015 – Syros Pharmaceuticals, the industry pioneer in gene control, announced today that accomplished industry veteran Kyle Kuvalanka joined the Company as its first Chief Operating Officer.  In this newly created role, Mr. Kuvalanka will hold broad management responsibility for finance, business development, new product planning, and other business operations, as well as the Company’s proprietary gene control mapping platform.“Syros is poised for ... 
Printer Friendly Version
09/08/15Syros Pharmaceuticals to Participate in September Investor Conferences
WATERTOWN, Mass., September 8, 2015 – Syros Pharmaceuticals, the leader in the discovery and development of novel gene control therapies for cancer and other serious diseases, announced today that management will participate in two investor conferences during the month of September: 22nd Annual NewsMakers in the Biotech Industry Conference, Thursday, September 10, 2015; Millennium Broadway Hotel, New York City. Management will present a corporate overview at 11:30 a.m. ET.2015 Morgan ... 
Printer Friendly Version
08/05/15Syros Pharmaceuticals to Participate in August Investor Conferences
WATERTOWN, Mass., August 5, 2015 – Syros Pharmaceuticals, the leader in the discovery and development of novel gene control therapies for cancer and other serious diseases, announced today that management will participate in two investor conferences during the month of August:2015 Wedbush PacGrow Healthcare Conference, Tuesday, August 11, 2015; Le Parker Meridien Hotel, New York City. Management will present a corporate overview at 8:00 a.m. ET.Citi Private Company Healthcare Technol... 
Printer Friendly Version
07/06/15Syros Pharmaceuticals Announces Appointment of CEO Nancy Simonian to BIO Board
WATERTOWN, Mass., July 6, 2015 – Syros Pharmaceuticals, the leader in the discovery and development of novel gene control therapies, announced today that Chief Executive Officer Nancy Simonian, M.D., has been appointed to the Biotechnology Industry Organization’s (BIO) Emerging Companies Section Governing Board. Dr. Simonian will join with other industry leaders to help shape a policy and legislative agenda for BIO that promotes the needs of emerging companies. “We are delighte... 
Printer Friendly Version
06/18/15Syros Pharmaceuticals to Present at 2015 JMP Securities Life Sciences Conference
WATERTOWN, Mass., June 18, 2015 – Syros Pharmaceuticals, the leader in the discovery and development of novel gene control therapies, announced today that Chief Financial Officer Jorge Conde will present a corporate overview at the 2015 JMP Securities Life Sciences Conference. The presentation will take place at 1:00 p.m. ET on Wednesday, June 24, 2015, at the St. Regis New York hotel in New York City. About Syros Pharmaceuticals Syros Pharmaceuticals is a therapeutics company ... 
Printer Friendly Version
05/31/15Biotech’s wellspring—a survey of the health of the private sector in 2014; Nature Biotechnology. Huggett, Brady
... 
Printer Friendly Version
05/02/15Five things you should know about Nancy Simonian; The Boston Globe. Weisman, Robert
... 
Printer Friendly Version
04/30/15Syros Pharmaceuticals Augments Senior Leadership Team
Adds significant depth to chemistry, corporate development and finance functionsWATERTOWN, MA, April 30, 2015 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, today announced the addition of three senior members to the company. Jonathan Garen joins the Company as Chief Business Officer; Christopher Roberts, Ph.D., as Vice President of Chemistry and Early Development; and Colleen DeSimone as Vice President of Financ... 
Printer Friendly Version
04/15/15Syros Pharmaceuticals to Present New Data from its Gene Control Platform in AML and Breast Cancer at AACR Annual Meeting 2015
- Research demonstrates how the comprehensive mapping of gene regulatory regions can illuminate clinically relevant subtypes and new therapeutic targets -WATERTOWN, MA, April 15, 2015 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today that it will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, which begins April 18. Syros' platform identif... 
Printer Friendly Version
03/20/15Syros Pharmaceuticals Announces New Research Published on Role of Cell Signaling Pathways in Gene Control
- Paper in Molecular Cell by Syros scientific founders validates approach to therapeutic gene control in cancers with signaling and transcriptional dependencies -WATERTOWN, MA, March 20, 2015 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today the publication of a study that demonstrated how gene control components, known as super-enhancers, act as functional units that concentrate multiple signaling pathway... 
Printer Friendly Version
02/24/15Syros Pharmaceuticals to Present at Leading Investor Conferences
WATERTOWN, MA, February 24, 2015, – Syros Pharmaceuticals,, a therapeutics company focused on discovering and developing novel gene control therapies, announced today that representatives from the company will be presenting at three investor conferences during the month of March. Cowen & Co. 35th Annual Health Care Conference, The Boston Marriott Copley Place, Boston, March 4, 2015 at 9:30 a.m. ET BioCentury 22ndAnnual Future Leaders in the Biotech Industry, Millennium Broadway Hotel and... 
Printer Friendly Version
02/23/15Syros Takes on Super-Enhancers; Chemical & Engineering News. Jarvis, Lisa
... 
Printer Friendly Version
02/18/15Syros Pharmaceuticals' CFO and Chief Product Officer Named to the Aspen Institute's 2015 Class of Henry Crown Fellows
Washington, DC, February 18, 2015 –– The Aspen Institute today announced its 2015 Class of Henry Crown Fellows, including Jorge Conde, Chief Financial Officer and Chief Product Officer of Syros Pharmaceuticals. The Henry Crown Fellowship mobilizes a new breed of leaders, all under the age of 45, to tackle the world's most intractable problems. All are proven entrepreneurs, mostly from the world of business, who have reached a point in their lives where, having achieved success, they are re... 
Printer Friendly Version
02/10/15Syros Pharmaceuticals Presents New Data on Use of its Gene Control Platform for Predicting Drug Response
- Abstract at AACR Translation of the Cancer Genome meeting describes novel approach to discovery of gene control biomarkers -WATERTOWN, MA, February 10, 2015 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today that data demonstrating the use of Syros’ gene control platform to identify biomarkers that predict drug response were presented at a recent meeting of cancer researchers. Research conducted by Syros... 
Printer Friendly Version
02/09/15Syros Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference
WATERTOWN, MA, February 9, 2015 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, will present a corporate overview at the 2015 Leerink Global Healthcare Conference, which takes place February 11 to 12, 2015, at the Waldorf Astoria Hotel in New York, New York. Syros CEO Nancy Simonian, MD, will present on Thursday, February 12, 2015, from 11:10 to 11:30 a.m. Eastern Time. About Syros Pharmaceuticals Syros Pharmac... 
Printer Friendly Version
01/07/15Syros Pharmaceuticals to Present at the 33rd Annual J.P. Morgan 2015 Healthcare Conference
WATERTOWN, MA, January 7, 2015 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, will present a corporate overview at the 33rd Annual J.P. Morgan Healthcare Conference, which takes place January 12 to 15, 2015, at the Westin St. Francis Hotel in San Francisco. The presentation by Syros CEO Nancy Simonian, MD, is scheduled for Tuesday, January 13, 2015, at 11:00 am Pacific Time in the Elizabethan C room at the Westin ... 
Printer Friendly Version